Weifang Shengtai holds unveiling ceremony for 'Joint University-Business Community Program' with HUT

NewsGuard 100/100 Score

Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTID) ("the Company") announced today that Weifang Shengtai Pharmaceutical, the Company's subsidiary in Changle, Shandong, China ("the Shandong Subsidiary"), held an unveiling ceremony for the "Joint University-Business Community Program" between the Company's Shandong subsidiary and the Hubei University of Technology ("HUT") in Changle, Shandong, China on December 4, 2010.  The ceremony officially kicked off the joint research and development program between the Company and HUT.  Based on the principles of mutual complementarity, equality and voluntary cooperation, the joint program represents a win-win opportunity for both the Company and HUT in terms of technology transformation by HUT and utilization of new technology by the Company.

One of the leading universities in Hubei, China, HUT is a source of strength for technology and talent. Its resources, especially those in aspects of education, training and research in biological engineering technology, are complementary to the Company's resources and leading position in the industry in China.  HUT's strength in the area of biological engineering technology sets it apart from many other universities in China and creates an opportunity for cooperation between HUT and the Company from the perspective of "mutual benefits, mutual complementarily and common development."  Under the joint program, new ideas, promotion and use of new technology, development of new products and solutions to technical problems will all be cooperatively implemented or carried out. HUT and the Company will work to seek breakthroughs in areas such as cost reduction, waste recycling, technological development of existing products and their derivatives and the development of new products.

The Company, HUT and the local government all have a high regard for the joint R&D program.  Seven people from HUT, numerous government officers (led by the Deputy Director of the Technology Bureau of Weifang City and the Governor of Changle County) and many business VIPs attended the ceremony.  Mr. Qingtai Liu, the CEO and Chairman of the Company, addressed the participants at the ceremony, and Mr. Shijie Dong, the Vice-Chancellor of HUT also made a speech. They exchanged letters of appointment and signed an agreement on building up the Company's research and development capabilities.  In addition, a funding contract for technology development was signed, in which Mr. Liu was appointed as the Director of the Management Committee of the fund. By the end of 2010, 500 thousand RMB will be paid to HUT in the first phase of the research and development program, and another 500 thousand RMB will be paid before Jun 2011 in the second phase of the research and development program. Both the Company and HUT agreed to try and obtain grants from the national, provincial and municipal governments through their funding programs for technology advancement.

In his address to the ceremony, Mr. Liu said that the Company continues to focus on operation and management and looks to take full advantage of technological progress. In the past, the Company's competitiveness has been increased through various joint research and development programs in production and products.  Going into the future, the Company will continue to actively seek opportunities for cooperation with universities and academics in a broad range of areas, such as the development of new products and promotion of technology innovation.  The Company expects to greatly benefit from its commitment to research and development and continuous use of new technology.

Source:

Shengtai Pharmaceutical, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses